Monitor FDA acceptance of the NDA after the 60-day review and subsequent PDUFA date assignment. The stock may rally on this milestone, but given prior poor performance of bullish calls on BLTE, consider taking partial profits on strength. The key catalyst is FDA approval decision, likely months away.
Price Chart
Executive Summary
Belite Bio completed rolling submission of its New Drug Application (NDA) to the FDA for tinlarebant, an oral therapy for Stargardt disease type 1 (STGD1), a rare retinal disease with no approved treatments. The NDA was submitted under Breakthrough Therapy Designation and will undergo a 60-day review; if accepted, a PDUFA target action date will be set. This is a pivotal regulatory milestone for the company's lead candidate, which met its Phase 3 DRAGON trial primary endpoint.
Key Facts
- Belite Bio completed rolling NDA submission to FDA for tinlarebant for Stargardt disease type 1 (STGD1).
- NDA submitted under Breakthrough Therapy Designation (BTD), granted due to high unmet need.
- STGD1 affects an estimated 53,000 people in the U.S. with no currently approved treatment options.
- Phase 3 DRAGON trial met its primary endpoint, showing tinlarebant significantly reduced growth rate of retinal lesions vs placebo.
- FDA will conduct a 60-day review period; if accepted, a PDUFA target action date will be assigned.
Financial Impact
No financial figures disclosed; potential first-to-market drug for a large unmet need in a rare disease with 53,000 U.S. patients.
Risk Factors
- FDA may not accept the NDA or may issue a Refuse to File letter.
- Even if accepted, FDA review could result in a Complete Response Letter requiring additional trials.
- Commercialization execution risk for a first-in-class oral therapy in a rare disease.
- Competition from other Stargardt disease programs in development.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-073668 |
| Document: tm2617120d1_6k.htm | 0001104659-26-073668 |
| Document: 0001104659-26-073668-index-headers.html | 0001104659-26-073668 |
| Document: 0001104659-26-073668-index.html | 0001104659-26-073668 |
| Document: 0001104659-26-073668.txt | 0001104659-26-073668 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 6-K | $147.34 | awaiting T+20 | — | $147.33 (−0.01%) |
Sep 9, 2026 6w ago | Insider Cluster | $175.07 $152.52 | ▲ +12.88% | ▲ +15.01% | $147.33 (+15.85%) |
Aug 12, 2026 10w ago | 6-K | $166.28 $173.79 | ▲ +4.52% | ▲ +6.26% | $147.33 (−11.40%) |
Aug 12, 2026 10w ago | Press Release | $166.28 $173.79 | ▲ +4.52% | ▲ +6.26% | $147.33 (−11.40%) |
Jun 12, 2026 19w ago | 6-K | $144.24 $147.03 | ▲ +1.93% | ▲ +2.68% | $147.33 (+2.14%) |
May 20, 2026 22w ago | Press Release | $143.36 $146.12 | ▲ +1.93% | ▲ +1.18% | $147.33 (+2.77%) |
Apr 21, 2026 26w ago | 6-K | $167.42 $139.70 | ▼ −16.56% | ▼ −19.72% | $147.33 (−12.00%) |
Apr 21, 2026 26w ago | Press Release | $167.42 $139.70 | ▼ −16.56% | ▼ −19.72% | $147.33 (−12.00%) |
Apr 9, 2026 28w ago | Insider Cluster | $181.17 $156.21 | ▲ +13.78% | ▲ +21.34% | $147.33 (+18.68%) |
Apr 9, 2026 28w ago | Insider Cluster | $181.17 $156.21 | ▲ +13.78% | ▲ +21.34% | $147.33 (+18.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers